Olema Entered into an Exclusive Worldwide License Agreement with Aurigene to Develop and Commercialize Novel Cancer Therapies
Shots:
- Aurigene to receive $8M up front to gain rights to a pre-existing Aurigene program, ~$60M in clinical development & regulatory milestones, ~$370M in commercial milestones along with royalties. Aurigene to get the funding for an ongoing discovery efforts
- The companies will jointly lead preclinical work, if successful, Olema will lead the clinical development, regulatory & commercial activities & remains well-capitalized to fund R&D operations until H2'24
- The collaboration combines Olema’s cancer biology & extensive development expertise with Aurigene’s expertise to develop new cancer treatments for women. Olema’s OP-1250 is being studied in P-I/II trial as monothx. & in P-Ib trial in combination with palbociclib for breast cancer
Ref: Globenewswire| Image: Olema
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
